Eliquis Management for Colonoscopy
For a colonoscopy, hold Eliquis (apixaban) for 3 days before the procedure (last dose 3 days prior), and restart it 2-3 days after the procedure once adequate hemostasis is achieved.
Pre-Procedure Management
The approach depends on whether your colonoscopy is diagnostic-only or involves therapeutic interventions:
Diagnostic Colonoscopy (Low-Risk)
- Simply omit the morning dose on the day of the procedure 1
- This is a weak recommendation based on low-quality evidence, but supported by the PAUSE trial which showed safety with 1-day interruption 1
Colonoscopy with Polypectomy or Biopsy (High-Risk)
- Hold Eliquis for 3 days before the procedure - meaning the last dose should be taken 3 days (72 hours) prior to the scheduled procedure 1
- This is a strong recommendation despite low-quality evidence
- The FDA label supports discontinuation at least 48 hours prior for procedures with moderate-to-high bleeding risk 2
Important caveat: Most colonoscopies are scheduled as potentially therapeutic (polyp removal may be needed), so the 3-day hold is the safer default approach unless you know definitively that no intervention will occur.
Post-Procedure Resumption
Restart Eliquis 2-3 days after the procedure once adequate hemostasis has been confirmed 1. The specific timing depends on:
- Low bleeding risk procedures (diagnostic only): Can resume at 1 day post-procedure
- High bleeding risk procedures (polypectomy, large biopsies): Resume at 2-3 days post-procedure
The PAUSE trial, which included over 3,000 patients on DOACs including apixaban, demonstrated low rates of major bleeding and thromboembolism with this standardized approach 1.
Key Clinical Considerations
No Bridging Required
Do not use bridging anticoagulation (heparin or LMWH) during the interruption period 3. Unlike warfarin management, DOACs like apixaban have rapid onset (full effect within 3 hours) and offset, making bridging unnecessary and potentially harmful 1.
Renal Function
While the guidelines focus on dabigatran dose adjustments for renal impairment, apixaban clearance can be prolonged in patients with significant kidney disease. One case report documented detectable apixaban levels for >10 days after the last dose in a patient with chronic kidney disease 4. If your patient has CrCl <30 mL/min or rapidly deteriorating renal function, consider consulting hematology 1.
Verification of Adequate Washout
Recent research shows that 94% of patients achieve clinically insignificant apixaban levels (≤30 ng/mL) when held for at least 48 hours, with median cessation time of 76 hours 5. The 3-day recommendation provides an appropriate safety margin.
Common Pitfalls to Avoid
- Don't double the dose to make up for missed doses during the hold period 2
- Don't restart too early - ensure hemostasis is adequate, particularly after polypectomy where delayed bleeding can occur
- Don't use INR or aPTT to monitor apixaban effect - these are unreliable 1
- Don't assume all colonoscopies are low-risk - default to the 3-day hold unless you're certain no therapeutic intervention will occur